Enhabit (NYSE:EHAB) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Enhabit (NYSE: EHAB) received a "sell (D-)" rating from Weiss Ratings, indicating negative sentiment from analysts.
• UBS Group lowered its price target for Enhabit shares from $10.00 to $8.50, maintaining a "neutral" rating.
• CFO Ryan Solomon acquired 10,000 shares of Enhabit stock, increasing his ownership stake by 5.45% amidst recent institutional investment activity.

Enhabit (NYSE:EHAB - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, UBS Group reduced their price target on shares of Enhabit from $10.00 to $8.50 and set a "neutral" rating on the stock in a research report on Friday, August 8th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Enhabit currently has a consensus rating of "Hold" and a consensus target price of $8.67.

Enhabit Trading Up 3.3%

NYSE EHAB traded up $0.26 during trading hours on Wednesday, reaching $8.22. The company had a trading volume of 211,510 shares, compared to its average volume of 384,214. The stock has a 50-day moving average of $7.79 and a 200 day moving average of $8.37. Enhabit has a 1-year low of $6.47 and a 1-year high of $10.90. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $416.67 million, a P/E ratio of -3.08 and a beta of 1.69.

Enhabit (NYSE:EHAB - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.03. Enhabit had a negative net margin of 12.84% and a positive return on equity of 2.72%. The company had revenue of $266.10 million for the quarter, compared to analysts' expectations of $263.39 million. As a group, research analysts anticipate that Enhabit will post 0.22 earnings per share for the current fiscal year.

Insider Activity

In other Enhabit news, CFO Ryan Solomon bought 10,000 shares of the business's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $7.64 per share, with a total value of $76,400.00. Following the transaction, the chief financial officer directly owned 193,468 shares in the company, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Osaic Holdings Inc. boosted its position in shares of Enhabit by 337.5% in the 2nd quarter. Osaic Holdings Inc. now owns 2,616 shares of the company's stock valued at $25,000 after purchasing an additional 2,018 shares during the period. GAMMA Investing LLC raised its stake in shares of Enhabit by 295.2% during the 1st quarter. GAMMA Investing LLC now owns 3,533 shares of the company's stock worth $31,000 after purchasing an additional 2,639 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Enhabit by 82.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,542 shares of the company's stock worth $44,000 after purchasing an additional 2,059 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Enhabit by 523.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,795 shares of the company's stock worth $56,000 after purchasing an additional 4,865 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of Enhabit by 110,987.5% in the 1st quarter. Jones Financial Companies Lllp now owns 8,887 shares of the company's stock valued at $78,000 after acquiring an additional 8,879 shares in the last quarter.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.